• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Thrombolytic therapies for ischemic stroke: Triumphs and future challenges.
Abstract Acute stroke therapy has significantly evolved over the last two decades. The two main advances have been the approval of intravenous chemical thrombolysis in 1995, and the approval of intra-arterial mechanical thrombectomy in 2015. This has lead to significant improvement of functional outcomes in a disease known to be the first cause of disability worldwide. Subsequent studies have focused on identifying pre-treatment predictors of good treatment candidates, by developing biochemical and imaging biomarkers. Different doses and agents of thrombolysis are also being tested. In this review article, we expl...
Source: Neuropharmacology - March 2, 2018 Category: Drugs & Pharmacology Authors: Moussaddy A, Demchuk AM, Hill MD Tags: Neuropharmacology Source Type: research

Effect of recombinant plasminogen activator timing on thrombolysis in a novel rat embolic stroke model
Publication date: Available online 30 March 2016 Source:Pharmacological Research Author(s): Yinzhong Ma, Li Li, Ziran Niu, Junke Song, Yihuang Lin, Huifang Zhang, Guanhua Du The treatment of acute ischemic stroke (AIS) using thrombolysis with recombinant tissue-plasminogen activator (rtPA, alteplase) is limited by its narrow time window and the risk of hemorrhage. Recombinant plasminogen activator (rPA, reteplase) has been used clinically on coronary artery thrombosis and acute myocardial infarction. It is necessary to induce strokes experimentally as a means of validating the rPA timing on patients with AIS. Howe...
Source: Pharmacological Research - March 30, 2016 Category: Drugs & Pharmacology Source Type: research

The role of calcium handling mechanisms in reperfusion injury.
Abstract Cardiovascular diseases, such as stroke and myocardial infarction (MI) remain the major cause of death and disability worldwide. However, the mortality of MI has declined dramatically over the past several decades because of advances in medicines (thrombolytic agents, antiplatelet drugs, beta blockers, and angiotensin converting enzyme inhibitors) and approaches to restore tissue perfusion(percutaneous coronary intervention and cardiopulmonary bypass). Animals studies have been shown that these treatments have been effective in reducing acute myocardial ischemic injury and limiting MI size. The paradox is...
Source: Current Pharmaceutical Design - November 20, 2018 Category: Drugs & Pharmacology Authors: Pittas K, Vrachatis DA, Angelidis C, Tsoucala S, Giannopoulos G, Defteros S Tags: Curr Pharm Des Source Type: research

Current Perspectives in Facilitated Angioplasty
Conclusions: With the current increased burden of acute coronary syndromes and the lack of immediate primary PCI facilities for all patients with STEMI, facilitated angioplasty seems a feasible therapeutic option. Another benefit of facilitated angioplasty may be represented by a major contribution of thrombolytic therapy in re-establishing microvascular myocardial blood flow.
Source: American Journal of Therapeutics - March 1, 2019 Category: Drugs & Pharmacology Tags: Systematic Reviews Source Type: research